Profile Response Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com


Molecular Profile CD274 positive
Therapy Paclitaxel + Pembrolizumab
Indication/Tumor Type ovary epithelial cancer
Response Type sensitive

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
CD274 positive ovary epithelial cancer sensitive Paclitaxel + Pembrolizumab FDA approved - On Companion Diagnostic Actionable In a Phase III trial (ENGOT-ov65/KEYNOTE-B96) that supported FDA approval, Keytruda (pembrolizumab) plus Taxol (paclitaxel), with or without Avastin (bevacizumab), significantly improved progression-free survival (8.3 vs 7.2 mo, HR 0.72, p=0.0014) and overall survival (18.2 vs 14.0 mo, HR 0.76, p=0.0053) in patients with CD274 (PD-L1)-positive (CPS>/=1) platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (Annals of Oncology, Volume 36, S1582; NCT05116189). detail... detail...
PubMed Id Reference Title Details
Keytruda (pembrolizumab) FDA Drug Label Full reference...
LBA3 Pembrolizumab vs placebo plus weekly paclitaxel ± bevacizumab in platinum-resistant recurrent ovarian cancer: Results from the randomized double-blind phase III ENGOT-ov65/KEYNOTE-B96 study Full reference...